|23 July 2012|
|Elan Announces Pfizer's Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials|
DUBLIN--(BUSINESS WIRE)--Jul. 23, 2012--
As referenced in the Pfizer announcement, Study 302 is the first of four placebo-controlled Phase 3 studies to complete a comprehensive development program of bapineuzumab IV. Jansen AI is leading two Phase 3 studies of patients who are ApoE4 carriers (Study 302) and non-carriers (Study 301) at sites primarily in
As further referenced in the announcement, the topline results from Study 301 in patients with mild - to - moderate Alzheimer's who do not carry the ApoE4 genotype will soon be available.
Elan is a neuroscience focused biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. For additional information about Elan, please visit http://www.elan.com.
|RSS Feeds | E-mail Alerts | Contact IR|